Unipath and Rohto settle patent litigation:
This article was originally published in Clinica
Unipath's parent company Unilever and Japanese company Rohto Pharmaceutical have settled a two-year patent dispute. The dispute, which related to immunoassays, especially Unipath's Clear series of pregnancy, diagnostic and ovulation testing kits, was heard in the Osaka district court. Rohto will pay undisclosed levels of compensation for its past use of the patent and will pay royalties for manufacturing and selling products based on the patent.
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.